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Abstract
Brain microvascular endothelial cells are a critical component of the blood-brain barrier. They 
form a tight monolayer which is essential for maintaining the brain homeostasis. Blood-derived 
proteases such as thrombin may enter the brain during pathological conditions like trauma, stroke, 
and inflammation and further disrupts the permeability of the blood-brain barrier, via incompletely 
characterized mechanisms. We examined the underlying mechanisms evoked by thrombin in rat 
brain microvascular endothelial cells (RBMVEC). Our results indicate that thrombin, acting on 
protease-activated receptor 1 (PAR1) increases cytosolic Ca2+ concentration in RBMVEC via 
Ca2+ release from endoplasmic reticulum through inositol 1,4,5-trisphosphate receptors and Ca2+ 
influx from extracellular space. Thrombin increases nitric oxide production; the effect is abolished 
by inhibition of the nitric oxide synthase or by antagonism of PAR1 receptors. In addition, 
thrombin increases mitochondrial and cytosolic reactive oxygen species production via PAR1-
dependent mechanisms. Immunocytochemistry studies indicate that thrombin increases F-actin 
stress fibers, and disrupts the tight junctions. Thrombin increased the RBMVEC permeability 
assessed by a fluorescent flux assay. Taken together, our results indicate multiple mechanisms by 
which thrombin modulates the function of RBMVEC and may contribute to the blood-brain 
barrier dysfunction.
Keywords
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1. Introduction
Endothelial cells of brain capillaries are an essential component of the blood-brain barrier; 
they contribute to brain homeostasis by forming a tight layer with reduced permeability 
(Abbott et al., 2010; Cardoso et al., 2010). The activity of brain microvascular endothelial 
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cells is modulated by G protein-coupled receptors agonists such as bradykinin, histamine, 
glutamate and thrombin through Ca2+-dependent mechanisms (Brown et al., 2008; De Bock 
et al., 2013; Kuhlmann et al., 2008; Li et al., 1999).
Thrombin is a blood-derived protease whose primary role is in coagulation and wound 
healing (Siller-Matula et al., 2011). During pathological conditions such as head trauma, 
stroke or inflammation, when the integrity of the blood-brain barrier is compromised, 
thrombin, and other blood-derived proteases may enter the brain and further impair the 
permeability of the blood-brain barrier (Cirino et al., 2000; Gingrich and Traynelis, 2000; 
Kuhlmann et al., 2008). In addition, brain endothelial cells can synthesize thrombin in 
neurodegenerative disorders like Alzheimer’s disease (Yin et al., 2010).
Thrombin has been reported to increase the permeability of endothelial cells from various 
vascular beds, including brain microvessels (Arce et al., 2008; Bartha et al., 2000; Kim et 
al., 2004; Siller-Matula et al., 2011); however, the mechanisms are incompletely understood. 
The effects of thrombin are largely mediated by protease-activated receptor 1 (PAR1), the 
first identified G protein-coupled receptor that is activated by proteolysis (Rasmussen et al., 
1991; Vu et al., 1991). Three additional proteinase-activated receptors (PARs) have been 
identified; PAR3 and PAR4 can be also activated by thrombin, while PAR2 is activated by 
trypsin (Alexander et al., 2015; Hollenberg and Compton, 2002).
Rat and human brain microvascular endothelial cells express thrombin receptors PAR1, 
PAR3 and PAR4 (Bartha et al., 2000; Kim et al., 2004; Vajda et al., 2008). Common 
signaling mechanisms downstream of thrombin-PARs interaction include activation of Gq/11 
proteins followed by mobilization of intracellular Ca2+ (Alexander et al., 2015; Hollenberg 
and Compton, 2002).
The endothelial cytosolic Ca2+ concentration, [Ca2+]i, is an essential determinant of 
paracellular permeability; an increase in [Ca2+] produces barrier dysfunction, by modulating 
the arrangement of junctional and cytoskeletal proteins (De Bock et al., 2013; Tiruppathi et 
al., 2002). Previous studies indicate that cytosolic Ca2+ plays a central role in the barrier 
disruption produced by thrombin (Kim et al., 2004; Sandoval et al., 2001). However, 
different Ca2+-dependent mechanisms are evoked by thrombin in different vascular beds 
(Arce et al., 2008; Sandoval et al., 2001). The current study examined the effects of 
thrombin on cytosolic Ca2+ concentration, nitric oxide, mitochondrial and cytosolic reactive 
oxygen species (ROS) production, cytoskeleton and tight junctions, and permeability, in rat 
brain microvascular endothelial cells.
2. Results
2.1. Thrombin increases cytosolic Ca2+ concentration, [Ca2+]i , in RBMVEC
In Fura-2 AM-loaded RBMVEC, thrombin (0.5 u/ml) increased the F340/F380 fluorescence 
ratio; representative examples of changes in ratio are shown in Fig. 1A. Pretreatment with 
the non-peptide PAR-1 antagonist, FR-171113 (1 μM, 15 min), prevented the thrombin-
induced increase in F340/F380 ratio (Fig. 1A). When the fluorescence ratio was converted to 
cytosolic Ca2+ concentration, [Ca2+]i, thrombin (0.1u/ml, 0.5 u/ml and 1 u/ml) produced a 
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fast and transient increase in [Ca2+]i in a dose-dependent manner. Examples of increases in 
[Ca2+]i are shown in Fig. 1B, and the comparison of the amplitude of [Ca2+]i increase 
produced by each concentration of thrombin tested and by thrombin (0.5 u/ml) in the 
presence of FR-171113 (1 μM) is shown in Fig. 1C. Thrombin (0.1u/ml, 0.5 u/ml and 1 
u/ml) increased [Ca2+]i by 52 ± 1.3 nM (n = 43), 412 ± 3.8 nM (n = 49), and 617 ± 4.2 nM 
(n = 51); this effect was abolished by FR-1711131 (n = 42).
2.2. Thrombin releases Ca2+ from endoplasmic reticulum
In Ca2+-free HBSS, thrombin (0.5 u/ml) produced an increase in [Ca2+]i of lower amplitude 
than in Ca2+-containing HBSS; Δ[Ca2+]i = 239 ± 2.7 nM (n = 47), as compared to 412 ± 3.8 
nM (Fig 2). When lysosomal Ca2+ stores were disrupted with bafilomycin A1 (1 μM, 1 h), a 
blocker of lysosomal ATPase (Bowman et al., 1988), thrombin (0.5 u/ml) increased [Ca2+]i 
by 227 ± 3.4 nM (n = 52), which was not significantly different from the response in the 
absence of bafilomycin A1. Blockade of ryanodine receptors with ryanodine (1 μM, 1 h) 
reduced the response to thrombin (Δ [Ca2+]i = 134 ± 2.6 nM) (n = 43), while blockade of 
while inositol 1,4,5 trisphosphate (IP3) receptors with xestospongin C (10 μM, 15 min) and 
2-APB (100 μM, 15 min) abolished the response to thrombin; Δ [Ca2+]i = 11 ± 1.4 nM (n = 
36) (Fig. 2).
2.3. Thrombin increases NO production in RBMVEC
In cells loaded with DAF-FM diacetate, a dye used to assess the NO levels (Kojima et al., 
1998), thrombin (0.5 u/ml) increased the DAF-FM fluorescence ratio by about 18% (Δ DAF-
FM = 0.18 ± 0.019) (n = 31). The response to thrombin was markedly reduced in cells 
pretreated with the NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME, 100 
μM), Δ DAF-FM = 0.05 ± 0.007 (n = 37) or with the PAR-1 antagonist, FR-171113 (1 μM) 
(Δ DAF-FM = 0.03 ± 0.008; n = 36) (Fig. 3). FR-171113 (1 μM) alone did not produce a 
statistically significant increase in the DAF-FM fluorescence ratio, as compared to control 
(Fig. 3).
2.4. Thrombin increases mitochondrial superoxide in RBMEC
The effect of thrombin on mitochondrial superoxide was assessed in RBMVEC loaded with 
MitoSOX Red, a dye that selectively targets mitochondria. Thrombin (0.5 u/ml) increased 
MitoSOX Red fluorescence by 47% (Δ MitoSOX Red = 0.47 ± 0.016; n = 37); this effect 
was prevented by the PAR-1 antagonist, FR-171113 (1 μM) (Δ MitoSOX Red = 0.06 
± 0.041; n = 39) (Fig. 4). FR-171113 (1 μM) alone did not significantly affect the MitoSOX 
Red fluorescence (Fig. 4).
2.5. Thrombin increases cytosolic ROS in RBMVEC
In RBMVEC loaded with CM-H2-DCFDA, a dye used for the assessment of cytosolic ROS, 
thrombin (0.5 u/ml) produced an increase in fluorescence by about 80% (Δ CM-H2-DCFDA 
= 0.838 ± 0.018) (n = 41) suggesting an increase in cytosolic ROS production. The response 
to thrombin was abolished by the PAR-1 antagonist, FR-171113, (Δ CM-H2-DCFDA = 
0.102 ± 0.063; n = 37) (Fig. 5); FR-171113 (1 μM) did not have a significant effect by itself 
(Fig. 5).
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2.6. Thrombin induces cytoskeletal changes
Immunocytochemistry studies examined the distribution of F-actin cytoskeleton and of 
ZO-1, a component of tight junctions (Abbott et al., 2010) before and after treatment with 
thrombin (0.5 u/ml), or thrombin in cells pretreated with the PAR1 antagonist, FR-171113 (1 
μM). Treatment with thrombin increased the F-actin stress fiber formation, and disrupted the 
tight junctions, as seen by the reduction of peripheral ZO-1 staining. In addition, thrombin 
promoted the intercellular gap formation (Fig. 6).
2.7. Thrombin increases RBMVEC permeability
Permeability of RBMVEC monolayer was assessed by FITC-dextran flux assay, as 
described (Monaghan-Benson and Wittchen, 2011). Confluent monolayers grown on PET 
inserts with 1 μm pores were treated with thrombin (0.5 u/ml), or thrombin (0.5 u/ml) and 
PAR1 antagonist (1 μM) and the fluorescence of the lower chamber was assessed at different 
time points (15 min, 30 min, 45 min, 1 h, 2h) using a plate reader. The fluorescence was 
significantly higher in samples from the lower chamber of thrombin-treated inserts; as 
compared with control samples, between 45 min and 2 hours (P<0.05) (Fig. 6B), indicating 
an increase in permeability.
3. Discussion
Thrombin, a serine protease produced by proteolysis of prothrombin at sites of vascular 
injury, has critical roles in coagulation and hemostasis. In addition, thrombin has pleiotropic 
effects in inflammation, proliferation, angiogenesis and vascular permeability (Siller-Matula 
et al., 2011). Thrombin increases permeability in various vascular beds such as pulmonary 
microvascular endothelial cells (Arce et al., 2008), rat and mouse cerebral microvascular 
endothelial cells (Bartha et al., 2000; Hawkins et al., 2015; Hun Lee et al., 2015; Wang et 
al., 2016), and human umbilical vein cells (Sandoval et al., 2001) by activating of 
proteinase-activated receptors (PARs).
In the present study, we examined the effects of thrombin on rat brain microvascular 
endothelial cells (RBMVEC), a key component of the blood-brain barrier. Since activation 
of PARs by thrombin has been reported to induce Gq/11-mediated signaling (Alexander et 
al., 2015; Hollenberg and Compton, 2002), and Ca2+ is an important second messenger 
involved in the regulation of barrier function (De Bock et al., 2013), we first investigated the 
effect of thrombin on cytosolic Ca2+ concentration, [Ca2+]i.
In RBMVEC, similarly to human cerebral microvascular endothelial cells (Kim et al., 2004; 
Li et al., 1999), rat brain capillary endothelial cells (Bartha et al., 2000; Brown et al., 2008), 
bovine pulmonary artery endothelial cells (Lum et al., 1992), human umbilical vein 
endothelial cells (HUVEC) and HUVEC-derived cell line ECV304 (Sandoval et al., 2001), 
thrombin increased [Ca2+]i. The magnitude of the Ca2+ response produced by thrombin in 
RBMVEC was dose-dependent. Treatment with the PAR1 antagonist, FR-171113 abolished 
the thrombin-induced Ca2+ response, indicating a critical role of PAR1 in this response. In 
endothelial cells, an increase in [Ca2+]i may be produced by Ca2+ influx and/or Ca2+ release 
from internal stores (Moccia et al., 2012). In the absence of extracellular Ca2+, the response 
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to thrombin was slightly reduced indicating the participation of Ca2+ influx in this response, 
as previously reported (Bartha et al., 2000; Sandoval et al., 2001). However, the fast and 
transient nature of the increase in [Ca2+]i produced by thrombin was suggestive of Ca2+ 
release from internal stores (Moccia et al., 2012).
We next explored the internal Ca2+ stores involved in the response to thrombin. Blockade of 
ryanodine receptors reduced, and that of inositol 1,4,5-trisphosphate (IP3) receptors 
abolished the response to thrombin, indicating that thrombin promoted the Ca2+ release from 
endoplasmic reticulum, mainly via IP3 receptors. On the other hand, inhibition of lysosomal 
ATPase did not affect the response, indicating that the endolysosomal Ca2+ stores are not 
involved in the response to thrombin. These results support the IP3-mediated Ca2+ release as 
the main mechanism of increase in [Ca2+]i by thrombin and a Gq/11 coupling mechanism of 
thrombin-PAR1 in RBMVEC. Activation of phospholipase C downstream to Gq protein 
pathway cleaves the membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2) 
to the second messengers inositol-1,4,5-trsphosphate (IP3) and diacylglycerol (DAG) 
(Berridge, 2009). Previous reports indicate an increase in IP3 within 10–15 seconds after 
stimulation with thrombin in bovine pulmonary artery endothelial cells (Lum et al., 1992) or 
HUVEC (Sandoval et al., 2001). IP3, acting on IP3 receptors, releases Ca2+ from 
endoplasmic reticulum. The local increase in Ca2+ further promotes Ca2+ release through 
ryanodine receptors, via Ca2+-induced Ca2+ release mechanism. The fact that thrombin-
induced increase in [Ca2+]i was reduced by blockade of ryanodine receptors, indicates that 
Ca2+ release from endoplasmic reticulum via ryanodine receptors, in addition to IP3 
receptors, is involved in the response to thrombin in RBMVEC. In endothelial cells, 
similarly with other cells, Ca2+ release from ER and the consequent depletion of the ER 
store leads to Ca2+ influx via store-operated Ca2+ entry (SOCE) (Putney, 1986; Tiruppathi et 
al., 2006). Our results indicate that in RBMVEC thrombin releases Ca2+ from ER store and 
promotes Ca2+ influx via SOCE (Fig. 7). We recently reported that SOCE is a functional 
mechanism of Ca2+ entry in RBMVEC (Brailoiu et al., 2016). Similarly, thrombin elicited 
SOCE in HUVEC (Sandoval et al., 2001) or in mouse lung microvascular endothelial cells 
(Tiruppathi et al., 2002).
We next investigated Ca2+-dependent pathways downstream of thrombin-PAR1 interaction 
in RBMVEC. An increase in NO production can occur via Ca2+-dependent activation of NO 
synthase (Fleming et al., 1997). Using a NO-sensitive fluorescent dye, we identified that 
thrombin increased NO in RBMVEC; the effect was abolished by the inhibition of PAR1 or 
of NO synthase. Similarly, thrombin induced a transient [Ca2+]i increase and NO production 
in pig coronary artery endothelial cells (Mizuno et al., 1998). In pulmonary endothelial cells, 
thrombin had a biphasic effect: the acute thrombin stimulation stimulated eNOS, while 
prolonged treatment inhibited the NO production (Nickel et al., 2013). In addition to its 
critical roles in vascular tone (Bohlen, 2015; Furchgott and Vanhoutte, 1989), NO modulates 
permeability of different microvascular beds, including the blood-brain barrier (Kubes and 
Granger, 1992; Thiel and Audus, 2001). Compounds like sodium nitroprusside, that 
spontaneously generate NO, increased the permeability of the blood-brain barrier in rats 
(Shukla et al., 1996)
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A local increase in cytosolic Ca2+ concentration, [Ca2+]i, is buffered by mitochondrial Ca2+ 
uptake (De Stefani et al., 2016) . Previous reports indicate that IP3-mediated increase in 
[Ca2+]i, may be transmitted to the mitochondria, increasing mitochondrial Ca2+ and 
bioenergetics (Hajnoczky et al., 1995). Intramitochondrial Ca2+ activates mitochondrion-
derived superoxide (mROS) production (Camello-Almaraz et al., 2006; Castilho et al., 
1998). Our results indicate that in RBMVEC thrombin increased mROS production via 
PAR1 activation. In murine and pulmonary pulmonary vein endothelial cells, thrombin-
evoked cytosolic Ca2+ mobilization was also followed by mROS increase (Hawkins et al., 
2007).
Generation of reactive oxygen species (ROS) has been involved in endothelial dysfunction 
(Craige et al., 2015). To investigate this pathway, we assessed the effect of thrombin on 
cytosolic ROS, monitored with a ROS-sensitive fluorescent dye (Deliu et al., 2012). We 
found that thrombin increased cytosolic ROS formation. Likewise, thrombin was found to 
generate ROS in platelets (Carrim et al., 2015). However, in platelets, thrombin exerted its 
effect via a PAR4-dependent mechanism, while our results support a PAR1-dependent 
mechanism in RBMVEC. On the other hand, in hepatocellular carcinoma cells, thrombin 
induced ROS via both PAR1 and PAR4 (Mussbach et al., 2015). In endothelial cells from a 
mouse model of Alzheimer’s disease, a direct thrombin inhibitor blocked ROS generation 
induced by hypoxia (Tripathy et al., 2013). To our knowledge, this is the first time when 
thrombin was shown to increase NO and ROS in RBMVEC.
In endothelial cells, similar to muscle cells, an increase in [Ca2+]i leads to activation of 
Ca2+/calmodulin-dependent myosin light chain (MLC) kinase (MLCK) , actin-myosin 
interaction, and cell retraction (Wysolmerski and Lagunoff, 1990) leading to increased 
permeability (De Bock et al., 2013). We examined the morphological changes induced by 
thrombin on the cytoskeleton and the tight junctions in RBMVEC. Thrombin increased F-
actin stress fibers, reduced the peripheral ZO-1 staining, and induced gap formation, 
indicating cytoskeletal changes and disruption of tight junctions, , and promoted an increase 
in permeability. These changes, consistent with barrier disruption, were similar to those 
reported in human or bovine pulmonary artery endothelial cells (Arce et al., 2008; Lum et 
al., 1992) or in mouse brain endothelial (bEnd.3) cells (Hun Lee et al., 2015) . Also, in 
pulmonary microvascular endothelial cells, thrombin was shown to increase the permeability 
and alter the barrier function by F-actin cytoskeleton rearrangement (Birukova et al., 2009; 
Wang et al., 2015). Taken together, our results indicate multiple mechanisms by which 
thrombin modulate the activity of rat brain microvascular endothelial cells and may disrupt 
the blood-brain barrier function, with implications for pathological conditions such as 
stroke, brain trauma and inflammation.
4. Experimental Procedures
4.1. Chemicals and reagents
Thrombin from human plasma and FR-171113 (PAR1 antagonist) were from Sigma-Aldrich 
(St. Louis, MO). Bafilomycin A1 and xestospongin C were from Tocris Biosciences (Bristol, 
UK). Fura-2AM, DAF-FM diacetate, DiBAC4(3), CM-H2-DCFDA, MitoSOX Red, and 
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ActinRed555 were from Molecular Probes (ThermoFisher Scientific, Waltham, MA). Other 
reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise mentioned.
4.2. Cell Culture
Rat brain microvascular endothelial cells (RBMVEC) from Cell Applications, Inc (San 
Diego, CA) were cultured in rat brain endothelial basal medium and endothelial growth 
supplements, according to the manufacturer’s instructions (Cell Applications, Inc), as 
previously described (Altmann et al., 2015; Brailoiu et al., 2016). Cells were grown in T75 
flasks coated with attachment factor (Cell Applications, Inc) until 80% confluent. Cells were 
plated on round coverslips of 12 mm diameter (immunocytochemistry studies), or 25 mm 
diameter (live imaging studies), coated with human fibronectin (Discovery Labware, 
Bedford, MA).
4.3. Cytosolic Ca2+ measurement
Measurements of intracellular Ca2+ concentration, [Ca2+]i, were performed as previously 
described (Altmann et al., 2015; Brailoiu et al., 2016). Briefly, cells were incubated with 5 
μM Fura-2 AM (Molecular Probes, ThermoFisher Scientific, Waltham, MA) in Hanks 
Balanced Salt Solution (HBSS) at room temperature for one hour and washed with dye-free 
HBSS. Coverslips were mounted in an open bath chamber (QR-40LP, Warner Instruments, 
Hamden, CT) on the stage of an inverted microscope Nikon Eclipse TiE (Nikon Inc., 
Melville, NY), equipped with a Perfect Focus System and a Photometrics CoolSnap HQ2 
CCD camera (Photometrics, Tucson, AZ). During the experiments, the Perfect Focus System 
was activated. Fura-2 AM fluorescence (emission 510 nm), following alternate excitation at 
340 and 380 nm, was acquired at a frequency of 0.25 Hz. Images were acquired/analyzed 
using NIS-Elements AR software (Nikon). After appropriate calibration, the ratio of the 
fluorescence signals (340/380 nm) was converted to Ca2+ concentrations (Grynkiewicz et 
al., 1985) .
4.4. NO measurement
Intracellular NO was monitored with DAF-FM [(4-amino-5-methylamino-2′,7′-difluoro-
fluorescein) diacetate] (Molecular Probes) as previously described (Altmann et al., 2015; 
Kojima et al., 1998). RBMVEC were incubated at room temperature for 45 min in HBSS 
containing a DAF-FM (0.5 μM) this condition significantly reduced the background auto-
fluorescence and improved the signal-to-noise ratio of NO detection in single cells (Leikert 
et al., 2001). After loading, cells were rinsed three times with saline. DAF-FM fluorescence 
ratio was measured using excitation and emission wavelengths of 488 nm and 540 nm, 
respectively, at a frequency of 0.1 Hz.
4.5. Detection of mitochondrial ROS accumulation
Measurement of mitochondrial ROS levels was carried out using the MitoSOX Red 
superoxide indicator (Molecular Probes), a novel and highly selective fluorogenic dye , as 
previously reported (Deliu et al., 2012). MitoSOX Red reagent permeates live cells, and 
rapidly and selectively targets mitochondria. At the mitochondrial level, it is rapidly 
oxidized by superoxide; oxidation of MitoSOX reagent leads to red fluorescence. Cells were 
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incubated with 3 μM MitoSOX Red in HBSS at room temperature for 25 min in the dark, 
and washed with dye-free HBSS. The intensity of red fluorescence after excitation at 510 
nm was acquired at a frequency of 0.25 Hz and evaluated as a measure of mitochondrial 
superoxide accumulation.
4.6. Detection of cytosolic ROS accumulation
Assessment of cytosolic ROS levels was achieved using CM-H2-DCFDA [5-6-
chloromethyl-27-dichlorodihydrofluorescein diacetate, acetyl ester] (Molecular Probes), as 
previously reported (Deliu et al., 2012). This assay is based on the principle that CMH2-
DCFDA passively diffuses into cells; its acetate groups are cleaved by intracellular esterases 
and its thiol-reactive chloromethyl group reacts with intracellular glutathione and other 
thiols. In the presence of ROS, CM-H2-DCFDA is rapidly oxidized to become highly 
fluorescent product that is trapped inside the cell. Cells were incubated with 1 μM CM-H2-
DCFDA in HBSS at room temperature for 15 min, in the dark and washed with dye-free 
HBSS. The intensity of green fluorescence following excitation at 495 nm was acquired at a 
frequency of 0.25 Hz and evaluated as a measure of cytosolic ROS accumulation.
4.7. Immunocytochemistry
Immunocytochemistry studies were carried out as previously described (Brailoiu et al., 
2011). RBMVEC grown on coverslips until confluence, were treated with thrombin (0.5 
u/ml) alone, or thrombin (0.5 u/ml) and FR-171113 (1 μM); untreated cells served as 
control. The cells were rinsed in PBS, fixed in 4% paraformaldehyde, washed with PBS and 
PBS with 0.5% Triton X for 5 min, blocked with normal goat serum, then incubated with 
primary antibody ZO-1 (rabbit IgG, Molecular Probes) overnight at 4ºC. After washing in 
PBS, the cells were incubated with secondary antibody conjugated to Alexa 488 goat anti-
rabbit, 2 hours at room temperature. After further washing with PBS, the cells were 
incubated for 30 min with ActinRed 555 (Molecular Probes), then washed in PBS, mounted 
with DAPI Fluoromount G (SouthernBiotech, Birgmingham, AL) and sealed. The cells were 
examined under a Leica DMI6000B fluorescence microscope equipped with the appropriate 
excitation/emission filters.
4.7 Permeability assay
RBMVEC were cultured in cell culture inserts with transparent PET membrane, 1 μm pore 
size (Corning/Falcon, Thomas Scientific) coated with human fibronectin, in 24 well plates, 
at a density of 3.5 × 104 cells/ insert, similarly with previous reports (Monaghan-Benson and 
Wittchen, 2011). Cells were grown until they reached confluence (2–3 days). In the day of 
the experiment, the growth medium was removed from the cell insert and replaced with 
medium containing Fluorescein isothiocyanate (FITC)-dextran 40,000 KDa (control) or the 
drug dissolved in medium containing FITC-dextran (treatment). FITC-dextran, 1mg/ml 
(Sigma-Aldrich) was freshly prepared just before the experiment. To quantify the passage of 
FITC-dextran across the cell monolayer, 50 ul of medium was removed from the bottom of 
the well and transferred to a 96-well plate at the time of treatment (0 min) and after 15, 30, 
45, 60 and 120 mins. The FITC intensity (excitation 480 nm, emission 520 nm) was 
measured using a Synergy 2 (Biotek Instruments Inc, Winooski, Vermont) plate reader. 
Experiments were carried out in triplicates.
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4.8. Statistical analysis
Data were expressed as mean ± standard error of mean (SEM). One-way ANOVA followed 
by post hoc analysis using Bonferonni and Tukey tests was used to evaluate significant 
differences between groups; P < 0.05 was considered statistically significant.
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Figure 1. Thrombin increases cytosolic Ca2+ concentration, [Ca2+]i , in RBMVEC
A, Examples of fura-2 AM fluorescence ratio (F340/F380) in RBMVEC before (basal) and 
after treatment with thrombin (0.5 u/ml), or thrombin (0.5 u/ml) in cells pretreated with the 
PAR-1 antagonist, FR-171113 (1 μM). Cold colors represent low ratios and hot colors 
represent high ratio (scale 0–2). B, Representative examples of [Ca2+]i increases produced 
by thrombin (0.1u/ml, 0.5 u/ml and 1 u/ml) and thrombin (0.5 u/ml) in the presence of 
FR-171113 (1 μM). Thrombin induced a fast and transient increase in [Ca2+]i whose 
amplitude was dose-dependent; the response to thrombin was abolished by FR-171113. C, 
Comparison of the amplitude of [Ca2+]i produced by each concentration of thrombin tested 
and by thrombin (0.5 u/ml) in the presence of FR-171113 (1 μM). P < 0.05 as compared to 
the response to the other concentrations of thrombin tested (*), or to the response produced 
by thrombin 0.5 u/ml (**).
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Figure 2. Thrombin releases Ca2+ from endoplasmic reticulum
A, Examples of increases in [Ca2+]i produced by thrombin in Ca2+-free HBSS, in the 
absence and presence of inhibitors of lysosomal and endoplasmic reticulum Ca2+ stores. 
Disruption of lysosomal Ca2+ stores with bafilomycin A1 (Baf, 1 μM, 1 h), did not affect the 
response to thrombin. Inhibition of ryanodine receptors with ryanodine (Ry, 1 μM, 1 h) 
reduced the response to thrombin, and blockade of IP3 receptors with xestospongin C (XeC, 
10 μM, 15 min) and 2-APB (100 μM, 15 min) abolished the response to thrombin. B, 
Comparison of the amplitude of Ca2+ responses produced by thrombin in each of the 
conditions mentioned. P < 0.05 as compared to the response to thrombin in Ca2+-free HBSS 
(*), or in the presence of ryanodine (**).
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Figure 3. Thrombin increases nitric oxide (NO) production in RBMVEC
A, Examples of increases in DAF-FM diacetate fluorescence ratio (F/F0), as a measure of 
NO level, produced by thrombin (0.5 u/ml) in the absence and presence of L-NAME and of 
PAR-1 antagonist, FR-171113 (1 μM). The effect of FR-171113 (1 μM) alone is also 
illustrated. B, Comparison of increases in Δ DAF-FM ratio in each of the conditions 
mentioned; L-NAME and FR-171113 abolished the response produced by thrombin. P < 
0.05 as compared to the basal level (*), or to the response produced by thrombin (**).
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Figure 4. Thrombin increases mitochondrial superoxide in RBMVEC
A, Examples of increases in MitoSOX Red fluorescence ratio (F/F0), as a measure of 
mitochondrial superoxide produced by thrombin (0.5 u/ml) in the absence and presence of 
the PAR-1 antagonist, FR-171113 (1 μM) or by FR-171113 (1 μM) alone. B, Comparison of 
increases in Δ MitoSOX Red fluorescence ratio produced by thrombin alone or in the 
presence of FR-171113. The PAR-1 antagonist abolished the response produced by 
thrombin. P < 0.05 as compared to the response produced by thrombin (*). P < 0.05 as 
compared to the basal level (*), or to the response produced by thrombin (**).
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Figure 5. Thrombin increases cytosolic ROS in RBMVEC
A, Examples of increases in CM-D2-DCFDA fluorescence ratio (F/F0), as a measure of ROS 
level, produced by thrombin (0.5 u/ml), FR-171113 (1μM) and thrombin in the presence of 
FR-171113(1 μM). B, Comparison of increases in Δ CM-D2-DCFDA ratio produced by 
thrombin alone, FR-171113 alone or thrombin in the presence of FR-171113. The PAR-1 
antagonist while did not have a significant effect by itself, abolished the response produced 
by thrombin. P < 0.05 as compared to the basal level (*), or to the response produced by 
thrombin (**).
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Figure 6. Morphological changes induced by thrombin in RBMVEC
A, Distribution of F-actin (red), a component of cytoskeleton, and ZO-1 (green), a 
component of tight junctions, in RBMVEC in control cells, cells treated with thrombin (0.5 
u/ml) or thrombin (0.5 u/ml) and FR-171113 (1 μM). Treatment with thrombin increased F-
actin stress fiber formation, produced a reduction in ZO-1 staining, indicating cytoskeletal 
rearrangement and disruption of tight junctions; in addition, intercellular gaps, indicated by 
arrows, became visible in the endothelial monolayer. Pretreatment with the PAR1 antagonist 
prevented the changes produced by thrombin. Cellular nuclei were stained with DAPI. B, 
Thrombin increased the permeability of RBMVEC monolayers assessed using the FITC-
dextran flux assay *P < 0.05 as compared to control.
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Figure 7. Proposed mechanism of thrombin effects in RBMVEC
Thrombin acting on PAR1, produces Ca2+ release from endoplasmic reticulum (ER) via 
inositol 1,4,5-trisphosphate receptors (IP3) receptors, and ryanodine receptors (RyR). 
Depletion of ER Ca2+ store leads to Ca2+ influx (store-operated Ca2+ entry, SOCE). The 
increase in [Ca2+]i promotes NO formation, increase mitochondrion-derived superoxide 
(mROS) and cytosolic ROS (cytoROS) levels and determines cytoskeletal changes (increase 
in F-actin stress fibers formation) and disruption of tight junctions, leading to increased 
permeability and barrier dysfunction. Abbreviations: PIP2 phosphatidylinositol-4,5-
bisphosphate; PLC, phospholipase C.
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